Whanin now under management of no borrowing.

Published: 2001-09-05 06:57:00

Updated: 2001-09-05 06:57:00

Amid a protracted economic recession now prevailed widely in Korea many business corporations are trying to keep their financial leverage more stable. In the pharmaceutical industry a company named Whanin has achieved a non-borrowing financial structure in Aug by paying back 2,300 million won of ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK